Cite
HARVARD Citation
Shebley, M. et al. (2023). Phase 1 study of safety, pharmacokinetics, and antiviral activity of SARS‐CoV‐2 neutralizing monoclonal antibody ABBV‐47D11 in patients with COVID‐19. Pharmacology research & perspectives. 11 (1), p. n/a. [Online].